Trial reportBMC cancer2025
Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials.
Trial report in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy-induced nausea and vomiting is a common adverse event of cancer treatments. Despite prophylactic antiemetic treatment, nausea remains a particular problem. We aimed to identify risk factors and clarify the usefulness of olanzapine for the control of carboplatin-induced nausea.
methodsThis was a pooled analysis of data from a single-arm, open-label, phase II trial and a prospective, randomized, double-blind, placebo-controlled phase III trial. We combined data from two trials with similar inclusion and exclusion criteria and treatment schedules. Chemotherapy-naïve patients aged ≥ 20 years with solid cancers who were scheduled to receive a first course of carboplatin-containing chemotherapy were enrolled. Patients in the olanzapine and placebo groups received olanzapine 5 mg or placebo, respectively, in combination with the neurokinin-1 (NK
resultsA total of 388 patients were evaluated (79.4% male, median age 72 years), including 208 patients in the olanzapine group. Overall, 87.5% in the olanzapine group and 75.0% in the placebo group were free of nausea (intergroup difference 12.5%, 95% CI, 4.7-20.3, p = 0.002), and the difference in proportion of patients reporting no appetite loss was 20.6% (95% CI, 11.5-29.6, p < 0.001). The overall complete response rates were 88.0% in the olanzapine group and 80.6% in the placebo group (p = 0.049). Multivariable analysis only identified no olanzapine use as significantly associated with a decreased risk of nausea (adjusted OR, 0.45, 95% CI, 0.26-0.76).
conclusionsThis analysis revealed that adding olanzapine to triple antiemetic therapy was associated with improved control of carboplatin-induced nausea.
trial registrationThe trial was registered with the University Hospital Medical Information Network Clinical Trial Registry (UMIN) 000026739, registered on 1 April 2017 and 000037749, registered on 1 September 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.